NeoImmuneTech (A950220) Q3 2025 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-17 as the lead candidate in both oncology and non-oncology indications.

• No commercial product sales yet; revenue generated from research services during development.

• Listed on KOSDAQ since 2021 as a technology growth company.

• Recent milestones include new clinical data, regulatory designations, and expanded global trials.

Financial highlights

• 2025 Q3 revenue: $39,666, all from research services; no product sales.

• Operating loss for 2025 Q3: $(13.5) million; net loss: $(14.9) million.

• Cash and cash equivalents at Q3 end: $41.2 million.

• Equity raised via rights offering in September 2025, increasing share count by 13.1 million.

• R&D expenses remain high, totaling $9.2 million for Q3 and $20.5 million YTD.

Outlook and guidance

• Expects first significant product revenue after FDA approval or licensing deals.

• Ongoing efforts to out-license NT-17 and expand indications, especially in ARS and oncology.

• Focus on achieving key clinical milestones and potential government supply contracts.